drugset / Trial / NCT00024180
FR901228 in Treating Patients With Hematologic Cancer
Phase 1
Completed
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.
Timeline
- Start
- 2002-01
- Primary completion
- —
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romidepsin | Peptide | 13 mg/m2 | Intravenous |